Divis' Laboratories Analyst Rating
based on 27 analysts
33.33%
Buy
18.52%
Hold
48.15%
Sell
Based on 27 analysts offering long term price targets for Divis' Laboratories. An average target of ₹5570.85
Source: S&P Global Market Intelligence
Divis' Laboratories Share analysis
Divis' Laboratories price forecast by 27 analysts
Downside of
High
₹6983
Target
₹5570.85
Low
₹3758
Divis' Laboratories target price ₹5570.85, a slight downside of -4.26% compared to current price of ₹5818.9. According to 27 analysts rating.
Excluding Excise Duty and Other Income, represents Net Revenue
Divis' Laboratories revenue growth forecast
Expected growth rate Q1, FY2027:63.84%
Forecast
Actual
Including amortisation and stock based compensations
Divis' Laboratories EPS growth forecast
EPS estimate Q1, FY2027:103.71%
Forecast
Actual
Source: S&P Global Market Intelligence
Divis' Laboratories Performance
Day's Low
Day's High
₹5,806.3Day's Price Range₹6,068.0552 Week's Low
52 Week's High
₹3,35052-Week Price Range₹6,285.45
| Returns % | |
| 1 Month Return | -0.52 % |
| 3 Month Return | + 0.02 % |
| 1 Year Return | + 60.95 % |
| Market Stats | |
| Previous Close | ₹6,000.60 |
| Open | ₹6,011.70 |
| Volume | 4.38L |
| Upper Circuit | - |
| Lower Circuit | - |
| Market Cap | ₹1,54,473.51Cr |
Divis' Laboratories Key Statistics
| P/E Ratio | 84.15 |
| PEG Ratio | 4.43 |
| Market Cap | ₹1,54,473.51 Cr |
| P/B Ratio | 6.75 |
| EPS | 60.38 |
| Dividend Yield | 0.87 |
| Sector | Pharmaceuticals |
| ROE | 12.04 |
Divis' Laboratories Peer Comparison
Company | Analyst View | Market Cap | 5 Year CAGR | Debt to Asset Ratio | Net Profit | Yearly Revenue |
|---|---|---|---|---|---|---|
| HOLD | ₹1,54,473.51 Cr | 42.73% | 0.50 | ₹1,600 Cr | ₹7,845 Cr | |
| BUY | ₹1,06,818.74 Cr | 43.1% | 0.67 | ₹1,656 Cr | ₹10,727 Cr | |
| BUY | ₹46,889.43 Cr | 6.69% | 0.58 | ₹1,297 Cr | ₹14,755 Cr | |
| HOLD | ₹27,335.61 Cr | -1.76% | 0.50 | ₹772 Cr | ₹5,664 Cr | |
| BUY | ₹1,15,327.28 Cr | 40.56% | 0.50 | ₹4,155 Cr | ₹25,774 Cr |
About Divis' Laboratories
Divis Laboratories Ltd's top products include APIs and intermediates for anti-infectives, cardiovascular, central nervous system, anti-diabetics, gastro-intestinal and anti-inflammatory treatments. The company is also a leader in the manufacture of custom synthesis and process development services for the global pharmaceutical industry.
Divis Laboratories Ltd is the proud owner of several popular brands, including Divis Life, Divis Pharma and Divis Health. Divis Life offers a range of health and wellness products, while Divis Pharma provides a wide range of APIs, intermediates and custom synthesis services.
Share Price: ₹5818.90 per share as on 21 Jan, 2025 04:01 PM
Market Capitalisation: ₹1,54,473.51Cr as of today
Revenue: ₹2,338.00Cr as on September 2024 (Q3 24)
Net Profit: ₹510.00Cr as on September 2024 (Q3 24)
Listing date: 12 Mar, 2003
Chairperson Name: Ramesh B V Nimmagadda
| Organisation | Divis' Laboratories |
| Headquarters | Hyderabad |
| Industry | Pharmaceuticals |
| E-voting on shares | Click here to vote |
Key events for Divis Laboratories Ltd
CITI Issues Buy Recommendation for Divis Laboratories - 14 Jan, 2025
CITI has given a buy recommendation for Divis Laboratories with a target price of Rs 6,850, highlighting a recent US court ruling and potential margin expansion.Divis Laboratories Launches Kakinada Greenfield Operations - 02 Jan, 2025
Divis Laboratories has commenced commercial operations at its Kakinada greenfield project, Phase I, on January 1, 2025, with significant investment plans. The project spans 200 acres of a 500-acre site.Divis Lab Positioned for GLP-1 Growth Opportunities - 23 Dec, 2024
Divis Laboratories is focusing on the GLP-1 drug opportunity, with improved quarterly performance and strong growth visibility in custom synthesis. Despite pricing erosion in the generic API business, the medium-term outlook remains positive, supported by the Kakinada facility's upcoming contributions. Analysts recommend accumulating the stock on market declines.
Insights on Divis Laboratories Ltd
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
POSITIVE IMPACTFII Holding Up
Foreign Institutions have increased holdings from 17.25% to 17.99% in Dec 2024 quarter
- POSITIVE IMPACT
Best in 1 Year
In the last 1 year, DIVISLAB has outperformed top 5 stocks with highest market-cap in Pharmaceuticals
- POSITIVE IMPACT
Revenue Rich
Revenue is up for the last 2 quarters, 2.19K Cr → 2.44K Cr (in ₹), with an average increase of 10.1% per quarter
- POSITIVE IMPACT
Price Rise
In the last 6 months, DIVISLAB stock has moved up by 25.3%
- POSITIVE IMPACT
Profit Spike
Netprofit is up for the last 2 quarters, 430.0 Cr → 510.0 Cr (in ₹), with an average increase of 15.7% per quarter
NO EFFECTAgainst Peers
In the last 3 years, Sun Pharmaceuticals Industries Ltd has given 103.2% return, outperforming this stock by 79.0%
- NO EFFECT
Promoter Holding Unchanged
Promoters holdings remained unchanged at 51.89% of holdings in Dec 2024 quarter
NEGATIVE IMPACTMF Holding Down
Mutual Funds have decreased holdings from 11.92% to 11.89% in Dec 2024 quarter
- NEGATIVE IMPACT
Retail Holding Down
Retail Investor have decreased holdings from 9.80% to 9.59% in Dec 2024 quarter
News
Capex Stocks Performance and Government Spending Insights Ahead of Budget 2025
Lloyds Metals & Energy, Dixon Technologies, Divis Laboratories, Coromandel International, Gujarat Fluorochemicals, Lupin, and SRF are among the 19 stocks that have defied the odds, delivering positive returns between 10% and 100%.21 Jan, 2025 10:42 AMAnalyst Recommendations: Buy Kotak Mahindra Bank, Bajaj Finserv, and Divi's Laboratories
Buy for a target price of ₹6,150 with a stop loss of ₹5,944 Analyst: Mitessh Thakkar of earningwaves.com at 9:15 am21 Jan, 2025 09:29 AMPharma Sector Stocks Show Mixed Movement in Early Trade
Aurobindo Pharma and Divis Labs also saw moderate gains, signaling selective interest in mid-cap pharma players.16 Jan, 2025 05:30 AMDivis' Laboratories Financials
Index Inclusions
Divis' Laboratories Shareholding Pattern
| Investors | Holdings % | FY Quarter | 3M change |
|---|---|---|---|
| Promoter Holdings | 51.89% | 0.00 | |
| Foreign Institutions | 17.99% | 4.26 | |
| Mutual Funds | 11.89% | ||
| Retail Investors | 9.59% | ||
| Others | 8.65% |
Divis' Laboratories Key Indicators
Divis' Laboratories Valuation
Divis' Laboratories in the last 5 years
Lowest (28.97x)
November 21, 2022
Industry (55.69x)
January 21, 2025
Today (84.15x)
January 21, 2025
Highest (90.48x)
December 4, 2024
Divis' Laboratories Earnings and Dividends
Divis Laboratories Ltd Dividends May,2024
In the quarter ending March 2024, Divis Laboratories Ltd has declared dividend of ₹30 - translating a dividend yield of 0.52%.
Read More about Dividends
Divis' Laboratories Technicals Summary
Bearish
Neutral
Bullish
Divis Laboratories Ltd is currently in a Bearish trading position according to technical analysis indicators.
FAQs on Divis Laboratories Ltd
Divis Laboratories Ltd share price today stands at ₹5818.9, Open. ₹6011.7 ; Previous Close. ₹6000.6 ; High. ₹6068.05 ; Low. ₹5806.3 ; 52 Week High. ₹6285.45 ; 52 Week Low: ₹3350.
- Get a PAN card.
- Open a Demat account.
- Open a Trading account.
- Link your Demat account to your Trading account.
- Fund your Trading account.
- Place an order to buy Divis Laboratories Ltd shares.
Divis Laboratories Ltd is listed on NSE
Divis Laboratories Ltd is listed on BSE
- Today’s highest price of Divis Laboratories Ltd is ₹6068.05.
- Today’s lowest price of Divis Laboratories Ltd is ₹5806.3.
PE Ratio of Divis Laboratories Ltd is 84.15
PE ratio = Divis Laboratories Ltd Market price per share / Divis Laboratories Ltd Earnings per share
Today’s traded volume of Divis Laboratories Ltd(DIVISLAB) is 4.38L.
Today’s market capitalisation of Divis Laboratories Ltd(DIVISLAB) is ₹154473.51Cr.
| Divis Laboratories Ltd(DIVISLAB | Price |
|---|---|
52 Week High | ₹6285.45 |
52 Week Low | ₹3350 |
Divis Laboratories Ltd(DIVISLAB) share price is ₹5818.9. It is down -7.42% from its 52 Week High price of ₹6285.45
Divis Laboratories Ltd(DIVISLAB) share price is ₹5818.9. It is up 73.70% from its 52 Week Low price of ₹3350
| Divis Laboratories Ltd(DIVISLAB | Returns |
|---|---|
1 Day Returns | -181.7% |
1 Month Returns | -0.52% |
3 Month Returns | 0.02% |
1 Year Returns | 60.95% |